

Imagion Biosystems Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Imagion Biosystems Limited
ABN:	42 616 305 027
Reporting period:	For the half-year ended 30 June 2025
Previous period:	For the half-year ended 30 June 2024

2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	(100.0%) to	-
Loss from ordinary activities after tax attributable to the owners of Imagion Biosystems Limited	up	8.8% to	(1,661,455)
Loss for the half-year attributable to the owners of Imagion Biosystems Limited	up	8.8% to	(1,661,455)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Consolidated Entity after providing for income tax amounted to \$1,661,455 (30 June 2024: \$1,526,829).

Refer to the “Review of Operations” section of the Directors’ Report for further commentary.

3. Net tangible assets

	30 Jun 2025 Cents	31 Dec 2024 Cents
Net tangible assets per ordinary security	(1.92)	(1.11)

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Imagion Biosystems Inc., a wholly owned subsidiary prepared its financial records in compliance with IFRS which is equivalent to Australian Accounting Standards.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Imagion Biosystems Limited for the half-year ended 30 June 2025 is attached.

12. Signed

Signed



Date: 27 August 2025

Imagion Biosystems Limited

ABN 42 616 305 027

Interim Report - 30 June 2025

For personal use only

Imagion Biosystems Limited
Contents
30 June 2025

Corporate directory	2
Directors' report	3
Auditor's independence declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the financial statements	10
Directors' declaration	20
Independent auditor's review report to the members of Imagion Biosystems Limited	21

Imagion Biosystems Limited
Corporate directory
30 June 2025

Directors	Mr Robert Proulx (Executive Chairman) Mr Brett Mitchell (Non-Executive Director) Ms Melanie Leydin (Non-Executive Director)
Company secretary	Ms Melanie Leydin
Registered office and principal place of business	Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000
Share registry	Boardroom Pty Limited Level 12, 225 George Street Sydney, NSW 2000
Auditor	RSM Australia Partners Level 27, 120 Collins Street Melbourne, VIC 3000
Australian legal advisor	Steinepreis Paganin Level 14, QV1 Building 250 St Georges Terrace Perth, WA 6000
United States legal advisor	Rimon, P.C. 1655 West Fairview Avenue, Suite 102 Boise, ID 83702
Stock exchange listing	Imagion Biosystems Limited shares are listed on the Australian Securities Exchange (ASX code: IBX)

Imagion Biosystems Limited
Directors' report
30 June 2025

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Consolidated Entity' or the 'Group') consisting of Imagion Biosystems Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2025.

Directors

The following persons were directors of Imagion Biosystems Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mr Robert Proulx (Executive Chairman)
Mr Brett Mitchell (Non-Executive Director)
Ms Melanie Leydin (Non-Executive Director)

Principal activities

During the financial year the principal continuing activities of the Consolidated Entity consisted of: Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance.

Review of operations

The loss for the Consolidated Entity after providing for income tax amounted to \$1,661,455 (30 June 2024: \$1,526,829).

The Consolidated Entity's main focus has been the continued development of the MagSense® HER2 Imaging Agent and the planned filing of Investigational New Drug (IND) application for Phase 2 study with the U.S. Food and Drug Administration (FDA).

Clinical development

In February 2025, the Consolidated Entity announced that it had initiated manufacturing of the MagSense® HER2 Imaging Agent for use in the planned Phase 2 clinical study.

In April 2025, the Consolidated Entity submitted a pre-IND Meeting Request and Meeting Package to the FDA to seek feedback on certain elements of the planned IND submission. Subsequent to the close of the quarter the Company reported that it had received written feedback and had met with FDA officials in a videoconference and, based on the feedback, the Consolidated Entity was prepared to move forward with the IND submission plan.

In May 2025, the Consolidated Entity enlisted Dr. William Dooley, surgical oncologist at the University of Oklahoma Health Sciences College of Medicine to serve as the Principal Investigator of the planned Phase 2 study. Dr. Dooley is a Professor in the Department of Surgery at the University of Oklahoma and is board certified by the American Board of Surgery. He received his medical degree at Vanderbilt and completed surgical training at Johns Hopkins Hospital and Oxford University before joining the Johns Hopkins faculty.

Additionally, the Consolidated Entity has engaged Dr. Leonardo Kayat-Bittencourt as a clinical advisor for the Company's prostate cancer program during the June 2025 quarter. Dr. Kayat-Bittencourt is Vice Chair of Innovation at University Hospitals and an Associate Professor of Radiology at Case Western Reserve University in Cleveland OH. Dr. Kayat-Bittencourt is a leader in the field of prostate cancer research using multiparametric MRI (mpMRI), with over 45 peer-reviewed publications and 110 conference abstracts. Dr. Kayat-Bittencourt has experience in both preclinical and clinical research in prostate cancer detection and therapies and will be instrumental in aligning Imagion's next steps for the development of the Company's MagSense® prostate cancer imaging agent with clinical needs.

Outlook

The Consolidated Entity expects to complete the manufacture of the MagSense® HER2 imaging agent in September 2025 quarter, and subsequently to file the IND. Commencement of the Phase 2 study is subject to approval of the IND by the FDA. The FDA is expected to respond to the Company's application in December 2025 quarter.

Expenditures for the prostate cancer and ovarian cancer programs will remain limited based on the availability of funds.

Significant changes in the state of affairs

On 7 April 2024, the Company announced that the unquoted 75,000,000 free attaching options which previously used ASX code IBXABC and the unquoted 22,500,000 options which previously used ASX code IBXAF, were granted with an official quotation IBXO on 8 April 2025. The terms for the options are detailed in the Notice of General Meeting lodged with ASX on 8 November 2024. All options with ASX code IBXO are exercisable at \$0.04 and they expire on 13 December 2027.

Imagion Biosystems Limited
Directors' report
30 June 2025

On 30 May 2025, the Company held an Annual General Meeting and obtained shareholders' approval to grant a total of 4,000,000 unlisted options (Director Options) to Mr Robert Proulx and Mr Brett Mitchell, as part of their remuneration.

There were no other significant changes in the state of affairs of the Consolidated Entity during the financial half-year.

Matters subsequent to the end of the financial half-year

On 4 August 2025, the Company announced that it has received \$3.5 million of firm commitments under a strongly supported capital raising.

The Placement will comprise of two tranches:

- (i) Tranche 1: Placement of 45.0 million new shares at \$0.015 per New Share to raise approximately \$0.675 million utilising the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A, and
- (ii) Tranche 2: The issue of the balance of shares, representing a value of approximately \$2.8 million, is conditional upon the Company obtaining shareholder approval at the Extraordinary General Meeting (EGM) to be held in September 2025.

Participants in both tranches of the placement are to receive one free attaching listed option per new share subscribed for, subject to approval of the shareholders at the EGM. The new listed options will be issued under the same terms as the Company's existing listed options (IBXO), exercisable at \$0.04 per listed option and expire on 13 December 2027.

On 11 August 2025, the Company confirmed it has received \$0.675m and settled Tranche 1 of its capital raising. 45.0 million fully paid ordinary shares were issued.

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years.

Rounding of amounts

The Group is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

On behalf of the directors


Robert Proulx
Executive Chairman

27 August 2025

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000

PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000

F +61 (0) 3 9286 8199

www.rsm.com.au**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the review of the financial report of Imagion Biosystems Limited and its Controlled Entity for the half year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

A blue ink signature, appearing to be "RSM", written in a cursive style.**RSM AUSTRALIA PARTNERS**A blue ink signature, appearing to be "BY Chan", written in a cursive style.

B Y CHAN
Partner

Dated: 27 August 2025
Melbourne, Victoria

Imagion Biosystems Limited
Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the half-year ended 30 June 2025

		Consolidated	
	Note	30 June 2025	30 June 2024
		\$	\$
Revenue			
Revenue and other income	4	25,734	1,197,769
Research & development tax incentives		-	437,279
		<u>25,734</u>	<u>1,635,048</u>
Expenses			
Research & development expenses		(611,595)	(332,853)
Professional fees		(317,903)	(292,864)
General expenses		(117,527)	(772,976)
Employee benefits expense		(104,375)	(774,665)
Depreciation and amortisation expense		(4,443)	(384,313)
Fair value movement of derivatives		168,152	-
Share-based payments expense		(21,505)	-
Finance costs		<u>(677,993)</u>	<u>(604,206)</u>
Loss before income tax expense		(1,661,455)	(1,526,829)
Income tax expense		<u>-</u>	<u>-</u>
Loss after income tax expense for the half-year attributable to the owners of Imagion Biosystems Limited		(1,661,455)	(1,526,829)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		<u>57,136</u>	<u>(21,921)</u>
Other comprehensive income for the half-year, net of tax		<u>57,136</u>	<u>(21,921)</u>
Total comprehensive income for the half-year attributable to the owners of Imagion Biosystems Limited		<u>(1,604,319)</u>	<u>(1,548,750)</u>
		Cents	Cents
Basic loss per share	11	(0.83)	(4.68)
Diluted loss per share	11	(0.83)	(4.68)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Imagion Biosystems Limited
Consolidated Statement of Financial Position
As at 30 June 2025

		Consolidated	31 December
	Note	30 June 2025	2024
		\$	\$
Assets			
Current assets			
Cash and cash equivalents		883,565	2,670,517
Trade and other receivables		884	886
Other current assets		34,981	114,042
Total current assets		<u>919,430</u>	<u>2,785,445</u>
Non-current assets			
Plant and equipment		13,045	18,274
Total non-current assets		<u>13,045</u>	<u>18,274</u>
Total assets		<u>932,475</u>	<u>2,803,719</u>
Liabilities			
Current liabilities			
Trade and other payables		1,497,558	2,239,398
Lease liabilities		1,398	53,787
Convertible notes and derivative financial instruments	5	3,299,313	2,793,514
Total current liabilities		<u>4,798,269</u>	<u>5,086,699</u>
Total liabilities		<u>4,798,269</u>	<u>5,086,699</u>
Net liabilities		<u>(3,865,794)</u>	<u>(2,282,980)</u>
Equity			
Issued capital	6	62,544,190	62,544,190
Reserves	7	2,264,014	2,185,373
Accumulated losses		<u>(68,673,998)</u>	<u>(67,012,543)</u>
Total equity		<u>(3,865,794)</u>	<u>(2,282,980)</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

Imagion Biosystems Limited
Consolidated Statement of Changes in Equity
For the half-year ended 30 June 2025

Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total Equity \$
Balance at 1 January 2024	59,605,923	4,921,408	(68,315,378)	(3,788,047)
Loss after income tax expense for the half-year	-	-	(1,526,829)	(1,526,829)
Other comprehensive income for the half-year, net of tax	-	(21,921)	-	(21,921)
Total comprehensive income for the half-year	-	(21,921)	(1,526,829)	(1,548,750)
<i>Transactions with owners in their capacity as owners:</i>				
Transfer from reserves	-	(3,369,792)	3,369,792	-
Share-based payments	-	62,889	-	62,889
Balance at 30 June 2024	<u>59,605,923</u>	<u>1,592,584</u>	<u>(66,472,415)</u>	<u>(5,273,908)</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 January 2025	62,544,190	2,185,373	(67,012,543)	(2,282,980)
Loss after income tax expense for the half-year	-	-	(1,661,455)	(1,661,455)
Other comprehensive income for the half-year, net of tax	-	57,136	-	57,136
Total comprehensive income for the half-year	-	57,136	(1,661,455)	(1,604,319)
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments (note 12)	-	21,505	-	21,505
Balance at 30 June 2025	<u>62,544,190</u>	<u>2,264,014</u>	<u>(68,673,998)</u>	<u>(3,865,794)</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Imagion Biosystems Limited
Consolidated Statement of Cash Flows
For the half-year ended 30 June 2025

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	-	1,061,221
Payments to suppliers and employees (inclusive of GST)	(1,799,331)	(1,709,724)
Interest received	25,734	3,147
Interest and other finance costs paid	(3,683)	(3,865)
Government grants and tax incentives	-	492,279
	<u>-</u>	<u>492,279</u>
Net cash used in operating activities	<u>(1,777,280)</u>	<u>(156,942)</u>
Cash flows from investing activities		
Proceeds from sale of assets	-	83,744
	<u>-</u>	<u>83,744</u>
Net cash from investing activities	<u>-</u>	<u>83,744</u>
Cash flows from financing activities		
Proceeds from the issue of convertible notes	-	220,000
	<u>-</u>	<u>220,000</u>
Net cash from financing activities	<u>-</u>	<u>220,000</u>
Net (decrease)/increase in cash and cash equivalents	(1,777,280)	146,802
Cash and cash equivalents at the beginning of the financial half-year	2,670,517	227,084
Effects of exchange rate changes on cash and cash equivalents	(9,672)	8,564
	<u>(9,672)</u>	<u>8,564</u>
Cash and cash equivalents at the end of the financial half-year	<u><u>883,565</u></u>	<u><u>382,450</u></u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Imagion Biosystems Limited as a Consolidated Entity consisting of Imagion Biosystems Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Imagion Biosystems Limited's functional and presentation currency.

Imagion Biosystems Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Registered office & Principal place of business

Suite 2, Level 11, 385 Bourke Street
Melbourne VIC 3000

A description of the nature of the Consolidated Entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 August 2025.

Note 2. Material accounting policy information

These general purpose financial statements for the interim half-year reporting period ended 30 June 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 December 2024 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Consolidated Entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Consolidated Entity.

Going concern

The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

As disclosed in the financial statements, the Consolidated Entity incurred a loss of \$1,661,455 (30 June 2024: \$1,526,829), and had net cash outflows from operating activities of \$1,777,280 (30 June 2024: \$156,942) for the half-year ended 30 June 2025 and, as of that date, the Consolidated Entity had net current liabilities of \$3,878,839 and net liabilities of \$3,865,794.

These factors indicate a material uncertainty which may cast significant doubt as to whether the Consolidated Entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report.

The Directors have prepared the financial statements for the Consolidated Entity on a going concern basis after consideration the following factors:

Note 2. Material accounting policy information (continued)

- As disclosed in Note 5, the Consolidated Entity has an approved facility with Mercer Street Global Opportunity Fund, LLC (Mercer) for \$10.78 million. The ability to draw down on the facility is subject to mutual agreement with Mercer and the Consolidated Entity having sufficient placement capacity.
- As disclosed in Note 10, the Consolidated Entity has settled Tranche 1 of its capital raising and has received \$0.675 million on 11 August 2025. Tranche 2 of the placement, raising a further \$2.8 million, is set to complete once shareholder approval is obtained at an Extraordinary General Meeting (EGM) scheduled for September 2025. Funds from the second tranche are expected to be received shortly after shareholder approval being granted at the EGM.

With these mitigating factors considered, the directors believe that the Consolidated Entity will be able to meet its debts as and when they fall due for a period of 12 months from the date of signing this financial report. On this basis, the directors believe that it is appropriate to adopt the going concern basis in the preparation of this financial report.

This financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessarily incurred should the Consolidated Entity not continue as a going concern.

Note 3. Operating segments

Identification of reportable operating segments

The Consolidated Entity is organised into one operating segment being Research & Development. This operating segment is based on internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers (CODM) in assessing performance and in determining the allocation of resources).

Geographical information

The Consolidated Entity has non-current assets and derives revenue in two geographical areas as outlined below:

	United States of America	Australia	Total
	\$	\$	\$
Consolidated - 30 June 2025			
Revenue			
Revenue and other income	-	25,734	25,734
Research & development tax incentives	-	-	-
Total revenue	<u>-</u>	<u>25,734</u>	<u>25,734</u>
Non-current assets			
Property, plant and equipment	<u>13,045</u>	<u>-</u>	<u>13,045</u>

	United States of America	Australia	Total
	\$	\$	\$
Consolidated - 30 June 2024			
Revenue			
Revenue and other income	1,195,379	2,390	1,197,769
Research & development tax incentives	-	437,279	437,279
Total revenue	<u>1,195,379</u>	<u>439,669</u>	<u>1,635,048</u>

Consolidated - 31 December 2024

Non-current assets			
Property, plant and equipment	<u>18,274</u>	<u>-</u>	<u>18,274</u>

Note 4. Revenue and other income

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Sales revenue:</i>		
Sale of goods	-	1,163,108
<i>Other revenue:</i>		
Interest income	25,734	2,390
Sub-lease revenue	-	32,271
	<u>25,734</u>	<u>1,197,769</u>

Geographical regions are disclosed in Note 3.

Note 5. Convertible notes and derivative financial instruments

	Consolidated	
	30 June 2025	31 December 2024
	\$	\$
<i>Current liabilities</i>		
Convertible notes payable	3,268,722	2,594,771
Embedded derivatives	30,591	198,743
	<u>3,299,313</u>	<u>2,793,514</u>

On 7 March 2023 the Consolidated Entity announced a funding package of up to \$15 million with Mercer Street Global Opportunity Fund, LLC, a New York based investment fund (Mercer). In 2023 financial year, the Company raised \$3,500,000 through the issue of 3,850,000 convertible notes ("2023 Notes").

During the year ended 31 December 2024, the following convertible notes ('2024 Note') were issued:

- (i) On 29 May 2024, the Company issued 242,000 Convertible Notes ('2024 Note') with a face value of \$1.00 per Note at a discounted subscription price of \$0.90909 and raised \$220,000 before costs. The Company also issued 2,048,122 options with an exercise price of \$0.11284 per option to the Note holders, with expiry on 29 May 2027.
- (ii) On 19 September 2024, the Company issued 550,000 2024 Notes with a face value of \$1.00 per 2024 Note and at a discounted subscription price of \$0.90909 to raise a maximum of approximately \$500,000 before costs. The Company also granted and issued 12,254,902 options with an exercise price of \$0.04284 per option to the Note holders, with expiry on 19 September 2027.

As at 30 June 2025, the available balance of the Mercer facility was \$10.78 million. This can be drawn by the Consolidated Entity, subject to mutual agreement with Mercer and the Consolidated Entity having sufficient placement capacity under the ASX Listing Rules or obtaining shareholder approval to issue the relevant securities.

All of the convertible notes have the following features:

Note 5. Convertible notes and derivative financial instruments (continued)

- Face value of \$1.00 at a subscription price of \$0.90909;
- No coupon is payable on drawn funds and no interest is payable on unconverted drawn funds;
- The conversion price is the higher of the 90% of the lowest VWAP during the 15 trading days immediately prior to issuing the relevant conversion notice or the floor price;
- Each convertible note provides Mercer with the option to convert the notes into ordinary shares. If Mercer does not convert the convertible notes by the relevant maturity dates (18 months from issue date), the Consolidated Entity is required to repay Mercer the face value of the notes; and
- The Consolidated Entity has the option to repay the convertible notes prior to the relevant maturity dates at 105% of the outstanding face value. At that time Mercer has the right to convert up to 30% of any outstanding face value prior to settlement.

On 17 July 2024, the Company executed a deed of variation ('Deed') with Mercer Street Global Opportunity Fund, LLC ('Mercer') in respect of convertible securities agreement entered into between the Company and Mercer on 7 March 2023 ('Convertible Securities Agreement'). The below table set out the variations to the Convertible Securities Agreement:

Matter	Particulars
Floor Price	\$0.04, subject to adjustment in accordance with the Convertible Securities Agreement.
Qualifying Capital Raising	<p>If a capital raising occurs which raises \$10,000,000 or more ('Qualifying Capital Raising'), the Company must give Mercer written notice of such event. In circumstances where: (a) the Qualifying Capital Raising is between \$10 million and \$15 million, Mercer may require repayment by the Company of some or all of up to 50% of the Notes; and (b) where the Qualifying Capital Raising is more than \$15 million, Mercer may require repayment by the Company of some or all of up to 100% of the Notes, by giving written notice to the Company no later than 20 Business Days after the date of the notice issued by the Company.</p> <p>Repayment of the nominated outstanding Notes must occur 5 Business Days after the date the on which notice is given to Mercer by the Company.</p>
Maturity Date	<p>(a) In respect of the First and Second tranches, the maturity date is 30 months from the date of issue.</p> <p>(b) In respect of the subsequent tranches, the Maturity Date is 18 months from the expiry date.</p>

Valuation methodology applied in valuing Convertible Notes

Upon issue of the Notes, the Group valued the Convertible Notes using the Black Scholes option pricing model to determine the value of the embedded derivative. The Black Scholes option pricing model assumes the option holder will exercise at expiry (i.e. the note will be converted on maturity) to predict the Group's possible future share prices to determine the Variable Conversion Price.

Significant unobservable inputs in applying this technique include the Company's future share price, exercise price, expiry date and volatility.

A Trinomial option valuation methodology has been used to determine the value of the Options issued to the noteholders.

Security

The Consolidated Entity, via entering into a general security deed, has granted Mercer Street Global Opportunity Fund, LLC a first ranking security against any present and after-acquired secured property and revolving assets.

Note 6. Issued capital

	Consolidated			
	30 June 2025	31 December 2024	30 June 2025	31 December 2024
	Shares	Shares	\$	\$
Ordinary shares - fully paid	201,341,415	201,341,415	62,544,190	62,544,190

Imagion Biosystems Limited
Notes to the financial statements
30 June 2025

Note 6. Issued capital (continued)

Movements in ordinary share capital

Details	Date	Shares	\$
Balance	1 January 2025	201,341,415	62,544,190
Balance	30 June 2025	<u>201,341,415</u>	<u>62,544,190</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 7. Reserves

	Consolidated 30 June 2025 \$	31 December 2024 \$
Foreign currency reserve	843,472	786,336
Share-based payments reserve	<u>1,420,542</u>	<u>1,399,037</u>
	<u>2,264,014</u>	<u>2,185,373</u>

Foreign currency reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services.

Movements in reserves

Movements in each class of reserve during the current financial half-year are set out below:

Consolidated	Share based payment reserve \$	Foreign currency reserve \$	Total \$
Balance at 1 January 2025	1,399,037	786,336	2,185,373
Foreign currency translation	-	57,136	57,136
Share-based payments for key management, non-executive directors and employees	<u>21,505</u>	<u>-</u>	<u>21,505</u>
Balance at 30 June 2025	<u>1,420,542</u>	<u>843,472</u>	<u>2,264,014</u>

Note 8. Fair value measurement

There are no assets or liabilities held at fair value on a recurring or non-recurring basis.

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature. The fair value of financial liabilities are estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

Embedded derivatives are measured at fair value in the statement of financial position are grouped into three levels of a fair value hierarchy:

The following tables detail the Consolidated Entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

Consolidated - 30 June 2025	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
<i>Liabilities</i>				
Embedded derivatives	-	-	30,591	30,591
Total liabilities	-	-	30,591	30,591

There were no transfers between levels during the financial half-year.

Reconciliation of the fair values at the beginning and end of the current half-year and previous financial year are set out below:

	Level 3	
	30 June 2025	31 December 2024
	\$	\$
Opening fair value	198,743	-
Addition of embedded derivatives of convertible note	-	17,702
Fair value (gains)/losses	(168,152)	181,041
	<u>30,591</u>	<u>198,743</u>

Note 8. Fair value measurement (continued)

Valuation techniques for fair value measurements categorised within level 3

Unobservable inputs used in calculating the embedded derivative classified as level 3 were expected future volatility and the risk-free rate. The expected future volatility was calculated at 110% and the risk-free rate used was 3.42%.

Embedded derivatives of convertible note

Derivative liability relates to convertible note facility (refer note 5 for further details). The conversion feature on this arrangement has a capped conversion price, the variable price also contains a floor. The existence of these caps and floors, means that this conversion feature is not considered to be an equity instrument in accordance with AASB 132, as it will not result in a fixed number of shares for fixed consideration. This conversion feature is a derivative and as a result changes in fair value are recognised through the profit and loss (FVTPL) in accordance with AASB 9. At initial recognition and subsequent reporting close, the derivative is required to be fair valued. The Black Scholes option pricing model assumes the option holder will exercise at expiry (i.e. the note will be converted on maturity) to predict the consolidated entity's possible future share prices to determine the Variable Conversion Price.

Sensitivity analysis

The sensitivity analysis undertaken on the unobservable inputs identified no material impact to the valuation at 30 June 2025.

Unobservable inputs used in calculating the embedded derivative classified as level 3 were expected future volatility and the risk-free rate. The expected future volatility was calculated at 110% and the risk-free rate used was 3.75%. There were no transfers between levels during the financial period.

Note 9. Contingent liabilities

As of 30 June 2025, the Company was not party to any material litigation, claims or suit whose outcome could have a material effect on the financial statements (31 December 2024: Nil).

Note 10. Events after the reporting period

On 4 August 2025, the Company announced that it has received \$3.5 million of firm commitments under a strongly supported capital raising.

The Placement will comprise of two tranches:

- (i) Tranche 1: Placement of 45.0 million new shares at \$0.015 per New Share to raise approximately \$0.675 million utilising the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A, and
- (ii) Tranche 2: The issue of the balance of shares, representing a value of approximately \$2.8 million, is conditional upon the Company obtaining shareholder approval at the Extraordinary General Meeting (EGM) to be held in September 2025.

Participants in both tranches of the placement are to receive one free attaching listed option per new share subscribed for, subject to approval of the shareholders at the EGM. The new listed options will be issued under the same terms as the Company's existing listed options (IBXO), exercisable at \$0.04 per listed option and expire on 13 December 2027.

On 11 August 2025, the Company confirmed it has received \$0.675m and settled Tranche 1 of its capital raising. 45.0 million fully paid ordinary shares were issued.

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years.

Note 11. Loss per share

Earnings per share for loss from continuing operations

Loss after income tax attributable to the owners of Imagion Biosystems Limited

	Consolidated
	30 June 2025 30 June 2024
	\$ \$

	<u>(1,661,455)</u>	<u>(1,526,829)</u>
--	--------------------	--------------------

Note 11. Loss per share (continued)

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Loss after income tax attributable to the owners of Imagion Biosystems Limited	<u>(1,661,455)</u>	<u>(1,526,829)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>201,341,415</u>	<u>32,646,551</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>201,341,415</u>	<u>32,646,551</u>
	Cents	Cents
Basic loss per share	(0.83)	(4.68)
Diluted loss per share	(0.83)	(4.68)

As at 30 June 2025, the Consolidated Entity has 123,732,515 options on issue. These options are considered to be non-dilutive whilst the Consolidated Entity is in a loss position.

Note 12. Share-based payments

Performance rights

Since listing on the Australian Stock Exchange, the Consolidated Entity has established various incentive arrangements to assist in the attraction, retention and motivation of its employees and management group.

Key Management Personnel and Directors

No performance rights were issued to key management personnel and directors in the half-year ended 30 June 2025.

The fair value of the performance rights, which were issued on 22 August 2024 to Mr Robert Proulx, Executive Chairman and Brett Mitchell, Non-executive Director, was determined using the Monte Carlo Simulation using the following inputs:

	Tranche 1	Tranche 2	Tranche 3
Number of performance rights granted	975,000	975,000	1,300,000
Grant date	22 August 2024	22 August 2024	22 August 2024
Expiry date	22 August 2028	22 August 2028	22 August 2028
Weighted average exercise price (\$)	-	-	-
Weighted average volatility %	97%	97%	97%
Weighted average risk-free rate %	3.534%	3.534%	3.534%
Fair value per performance right \$	0.0370	0.0338	0.0309
Fair value of performance right \$	\$36,075	\$32,955	\$40,170

During the half-year ended 30 June 2025, share-based payment of \$16,186 has been recognised in the statement of profit or loss of the Consolidated Entity for the performance rights.

Options

A share option plan has been established by the Consolidated Entity and approved by shareholders at a general meeting, whereby the Consolidated Entity may, at the discretion of the Board, grant options over ordinary shares in the Company to certain key management personnel of the Consolidated Entity. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Board.

Contractor

The Company's Chief Business Officer was granted 1,500,000 options on 30 May 2025. The option exercise price is \$0.012, expiring on 29 May 2030. The vesting conditions are as follows:

Note 12. Share-based payments (continued)

Milestone	Number of options	Vesting conditions
1	300,000	Submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction)
2	300,000	First patient dosed in a Phase 2 study (not including Phase 1b)
3	750,000	Completion of Phase 2 study
4	150,000	Submission of an IND (or like regulatory approval) for a second imaging agent

Key Management Personnel and Directors

On 30 May 2025, 2,000,000 unlisted options were granted to Mr Robert Proulx with exercise price \$0.012, expiring on 29 May 2030 and with the following vesting conditions:

Milestone	Number of options	Vesting conditions
1	400,000	Submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction)
2	400,000	First patient dosed in a Phase 2 study (not including Phase 1b)
3	1,000,000	Completion of Phase 2 study
4	200,000	Submission of an IND (or like regulatory approval) for a second imaging agent

On 30 May 2025, 2,000,000 unlisted options were granted to Mr Brett Mitchell with exercise price \$0.019, expiring on 29 May 2028. 666,667 options vested immediately at the date of issue, 10 July 2025. The next batch of 666,667 options will vest on 10 July 2026 and the remaining 666,666 options will vest on 10 July 2027.

During the half-year ended 30 June 2025, share-based payment of \$5,319 has been recognised in the statement of profit or loss of the Consolidated Entity for the 5,500,000 options.

Set out below are summaries of options granted under the plan in prior periods:

30 June 2025

Grant date	Expiry date	Exercise price	Balance at the start of the half-year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the half-year
01/06/2020	01/05/2026	\$1.120	68,750	-	-	-	68,750
01/06/2020	01/05/2027	\$1.120	68,750	-	-	-	68,750
01/06/2020	01/05/2028	\$1.120	50,000	-	-	-	50,000
14/12/2021	30/11/2030	\$3.490	100,000	-	-	-	100,000
09/12/2024	13/12/2027	\$0.040	75,000,000	-	-	-	75,000,000
09/12/2024	13/12/2027	\$0.040	3,125,000	-	-	-	3,125,000
09/12/2024	13/12/2027	\$0.040	22,500,000	-	-	-	22,500,000
			100,912,500	-	-	-	100,912,500
Weighted average exercise price			\$0.045	\$0.000	\$0.000	\$0.000	\$0.045

The options which the Company has issued to Mercer pursuant to Convertible Securities Agreement executed on 7 March 2023 are as follows:

Note 12. Share-based payments (continued)

Grant date	Expiry date	Exercise Price	Number under option
21/03/2023	21/03/2026	\$1.49600	353,474
31/05/2023	26/05/2026	\$1.49600	699,897
01/06/2023	01/06/2026	\$1.49600	702,248
25/08/2023	25/08/2026	\$0.90000	1,164,597
29/05/2024	29/05/2027	\$0.11284	2,048,122
10/09/2024	10/09/2027	\$0.04284	12,254,902
			<u>17,223,240</u>

For the options granted during the current financial half-year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
30/05/2025	29/05/2030	\$0.013	\$0.012	112.000%	-	3.547%	\$0.0106
30/05/2025	29/05/2028	\$0.013	\$0.019	112.000%	-	3.325%	\$0.0081

Imagion Biosystems Limited
Directors' declaration
30 June 2025

In the directors' opinion:

- the attached financial statements and notes comply with the *Corporations Act 2001*, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Consolidated Entity's financial position as at 30 June 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the *Corporations Act 2001*.

On behalf of the directors


Robert Proulx
Executive Chairman

27 August 2025

For personal use only

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199

www.rsm.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT

To the Members of Imagion Biosystems Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Imagion Biosystems Limited ("the company") and its Controlled Entity (together "the consolidated entity") which comprises the consolidated statement of financial position as at 30 June 2025, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the consolidated entity is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Imagion Biosystems Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the half-year financial report, which indicates the consolidated entity incurred a loss of \$1,661,455 and had net cash outflows from operating activities of \$1,777,280 for the half year ended 30 June 2025, and as at that date the consolidated entity had net current liabilities of \$3,878,839 and net liabilities of \$3,865,794. As stated in Note 1, these conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the consolidated entity's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Responsibility of the Directors' for the Financial Report

The directors of Imagion Biosystems Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



RSM AUSTRALIA PARTNERS



B Y CHAN
Partner

Dated: 27 August 2025
Melbourne, Victoria